CMG Pharmaceutical（A058820）株式概要製薬会社であるCMG Pharmaceutical Co., Ltd.は、韓国で経口薄膜（OTF）医薬品の開発・販売を行っている。 詳細A058820 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析過去5年間で収益は年間83.7%減少しました。 意味のある時価総額がありません ( ₩108B )すべてのリスクチェックを見るA058820 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW477,573 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA477,573 investors already sharing narrativesYour Fair Value₩Current Price₩730.0055.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-8b110b2016201920222025202620282031Revenue ₩110.1bEarnings ₩16.5bAdvancedSet Fair ValueView all narrativesCMG Pharmaceutical Co., Ltd. 競合他社Kookjeon PharmaceuticalSymbol: KOSDAQ:A307750Market cap: ₩107.4bKyongbo PharmaceuticalSymbol: KOSE:A214390Market cap: ₩121.7bKyung Dong PharmaceuticalSymbol: KOSDAQ:A011040Market cap: ₩130.5bDongKoo Bio & PharmaSymbol: KOSDAQ:A006620Market cap: ₩104.0b価格と性能株価の高値、安値、推移の概要CMG Pharmaceutical過去の株価現在の株価₩730.0052週高値₩2,205.0052週安値₩643.00ベータ0.431ヶ月の変化-25.96%3ヶ月変化-58.85%1年変化-61.21%3年間の変化-70.08%5年間の変化-85.46%IPOからの変化-67.98%最新ニュースお知らせ • Jul 07CMG Pharmaceutical Co., Ltd. announced that it has received KRW 45 billion in funding from Korea Investment & Securities Co., Ltd.On July 7, 2026, CMG Pharmaceutical Co., Ltd. closed the offering.New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩154.5b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 84% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩154.5b market cap, or US$99.0m).お知らせ • Mar 13CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 248, seohaean-ro, gyeonggi-do, siheung South Korea分析記事 • Jan 28Does CMG Pharmaceutical (KOSDAQ:058820) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Nov 28CMG Pharmaceutical Co., Ltd.'s (KOSDAQ:058820) Business Is Yet to Catch Up With Its Share PriceWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...Reported Earnings • Nov 19Third quarter 2025 earnings released: EPS: ₩39.00 (vs ₩19.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩39.00 (up from ₩19.00 loss in 3Q 2024). Revenue: ₩30.4b (up 23% from 3Q 2024). Net income: ₩5.73b (up ₩8.41b from 3Q 2024). Profit margin: 19% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.最新情報をもっと見るRecent updatesお知らせ • Jul 07CMG Pharmaceutical Co., Ltd. announced that it has received KRW 45 billion in funding from Korea Investment & Securities Co., Ltd.On July 7, 2026, CMG Pharmaceutical Co., Ltd. closed the offering.New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩154.5b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 84% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩154.5b market cap, or US$99.0m).お知らせ • Mar 13CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 248, seohaean-ro, gyeonggi-do, siheung South Korea分析記事 • Jan 28Does CMG Pharmaceutical (KOSDAQ:058820) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Nov 28CMG Pharmaceutical Co., Ltd.'s (KOSDAQ:058820) Business Is Yet to Catch Up With Its Share PriceWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...Reported Earnings • Nov 19Third quarter 2025 earnings released: EPS: ₩39.00 (vs ₩19.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩39.00 (up from ₩19.00 loss in 3Q 2024). Revenue: ₩30.4b (up 23% from 3Q 2024). Net income: ₩5.73b (up ₩8.41b from 3Q 2024). Profit margin: 19% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (64% accrual ratio).New Risk • May 23New major risk - Revenue and earnings growthEarnings have declined by 1.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.2% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).New Risk • Apr 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.7% net profit margin).New Risk • Mar 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.7% Last year net profit margin: 6.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.7% net profit margin).分析記事 • Mar 26Is CMG Pharmaceutical (KOSDAQ:058820) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...お知らせ • Mar 13CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 248, seohaean-ro, gyeonggi-do, siheung South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.New Risk • Dec 09New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.分析記事 • Nov 20There May Be Reason For Hope In CMG Pharmaceutical's (KOSDAQ:058820) Disappointing EarningsThe market for CMG Pharmaceutical Co., Ltd.'s ( KOSDAQ:058820 ) shares didn't move much after it posted weak earnings...Reported Earnings • Nov 15Third quarter 2024 earnings released: ₩19.00 loss per share (vs ₩19.00 profit in 3Q 2023)Third quarter 2024 results: ₩19.00 loss per share (down from ₩19.00 profit in 3Q 2023). Revenue: ₩24.7b (up 5.0% from 3Q 2023). Net loss: ₩2.68b (down 199% from profit in 3Q 2023).New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 20% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: ₩43.00 (vs ₩27.00 in 2Q 2023)Second quarter 2024 results: EPS: ₩43.00 (up from ₩27.00 in 2Q 2023). Revenue: ₩24.9b (down 2.3% from 2Q 2023). Net income: ₩5.98b (up 62% from 2Q 2023). Profit margin: 24% (up from 14% in 2Q 2023).Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩2,000, the stock trades at a trailing P/E ratio of 46.3x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 59% over the past three years.分析記事 • Mar 27CMG Pharmaceutical's (KOSDAQ:058820) Solid Earnings Are Supported By Other Strong FactorsCMG Pharmaceutical Co., Ltd. ( KOSDAQ:058820 ) just reported healthy earnings but the stock price didn't move much. We...Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Is New 90 Day High Low • Feb 24New 90-day low: ₩4,400The company is down 5.0% from its price of ₩4,630 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.分析記事 • Dec 28Did You Participate In Any Of CMG Pharmaceutical's (KOSDAQ:058820) Fantastic 203% Return ?It's been a soft week for CMG Pharmaceutical Co., Ltd. ( KOSDAQ:058820 ) shares, which are down 13%. But that doesn't...Is New 90 Day High Low • Dec 18New 90-day high: ₩6,350The company is up 38% from its price of ₩4,605 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.Is New 90 Day High Low • Dec 02New 90-day high: ₩5,050The company is up 11% from its price of ₩4,540 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day high: ₩4,900The company is up 13% from its price of ₩4,355 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.株主還元A058820KR PharmaceuticalsKR 市場7D-9.9%-4.4%-1.4%1Y-61.2%-14.8%99.2%株主還元を見る業界別リターン: A058820過去 1 年間で-14.8 % の収益を上げたKR Pharmaceuticals業界を下回りました。リターン対市場: A058820は、過去 1 年間で99.2 % のリターンを上げたKR市場を下回りました。価格変動Is A058820's price volatile compared to industry and market?A058820 volatilityA058820 Average Weekly Movement8.7%Pharmaceuticals Industry Average Movement7.1%Market Average Movement9.8%10% most volatile stocks in KR Market17.7%10% least volatile stocks in KR Market5.1%安定した株価: A058820 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A058820の 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2001223Joohyung Leewww.cmgpharma.co.kr製薬会社であるCMG Pharmaceutical Co., Ltd.は、韓国で経口薄膜（OTF）医薬品の開発・販売を行っている。勃起不全治療薬タダラフィルOTF製品、B型肝炎治療薬エンテカビルOTF製品、統合失調症治療薬アリピプラゾールOTF製品、喘息・アレルギー性鼻炎治療薬モンテルカストOTF製品を提供している。CMG Pharmaceutical Co Ltd.はHandok Inc.とがん治療に関する戦略的提携契約を締結している。同社は以前はスカイニューファーム株式会社として知られていたが、2013年4月にCMGファーマシューティカル株式会社に社名を変更した。CMGファーマシューティカル株式会社は2001年に設立され、韓国のソウルに本社を置いています。もっと見るCMG Pharmaceutical Co., Ltd. 基礎のまとめCMG Pharmaceutical の収益と売上を時価総額と比較するとどうか。A058820 基礎統計学時価総額₩108.13b収益（TTM）-₩8.38b売上高(TTM)₩110.12b1.0xP/Sレシオ-12.9xPER（株価収益率A058820 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A058820 損益計算書（TTM）収益₩110.12b売上原価₩47.55b売上総利益₩62.57bその他の費用₩70.96b収益-₩8.38b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-56.59グロス・マージン56.82%純利益率-7.61%有利子負債／自己資本比率43.6%A058820 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 07:52終値2026/07/31 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CMG Pharmaceutical Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 07CMG Pharmaceutical Co., Ltd. announced that it has received KRW 45 billion in funding from Korea Investment & Securities Co., Ltd.On July 7, 2026, CMG Pharmaceutical Co., Ltd. closed the offering.
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩154.5b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 84% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩154.5b market cap, or US$99.0m).
お知らせ • Mar 13CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 248, seohaean-ro, gyeonggi-do, siheung South Korea
分析記事 • Jan 28Does CMG Pharmaceutical (KOSDAQ:058820) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Nov 28CMG Pharmaceutical Co., Ltd.'s (KOSDAQ:058820) Business Is Yet to Catch Up With Its Share PriceWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...
Reported Earnings • Nov 19Third quarter 2025 earnings released: EPS: ₩39.00 (vs ₩19.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩39.00 (up from ₩19.00 loss in 3Q 2024). Revenue: ₩30.4b (up 23% from 3Q 2024). Net income: ₩5.73b (up ₩8.41b from 3Q 2024). Profit margin: 19% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 07CMG Pharmaceutical Co., Ltd. announced that it has received KRW 45 billion in funding from Korea Investment & Securities Co., Ltd.On July 7, 2026, CMG Pharmaceutical Co., Ltd. closed the offering.
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩154.5b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 84% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩154.5b market cap, or US$99.0m).
お知らせ • Mar 13CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 248, seohaean-ro, gyeonggi-do, siheung South Korea
分析記事 • Jan 28Does CMG Pharmaceutical (KOSDAQ:058820) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Nov 28CMG Pharmaceutical Co., Ltd.'s (KOSDAQ:058820) Business Is Yet to Catch Up With Its Share PriceWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...
Reported Earnings • Nov 19Third quarter 2025 earnings released: EPS: ₩39.00 (vs ₩19.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩39.00 (up from ₩19.00 loss in 3Q 2024). Revenue: ₩30.4b (up 23% from 3Q 2024). Net income: ₩5.73b (up ₩8.41b from 3Q 2024). Profit margin: 19% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (64% accrual ratio).
New Risk • May 23New major risk - Revenue and earnings growthEarnings have declined by 1.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.2% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
New Risk • Apr 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.7% net profit margin).
New Risk • Mar 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.7% Last year net profit margin: 6.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.7% net profit margin).
分析記事 • Mar 26Is CMG Pharmaceutical (KOSDAQ:058820) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
お知らせ • Mar 13CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 248, seohaean-ro, gyeonggi-do, siheung South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.
New Risk • Dec 09New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.
分析記事 • Nov 20There May Be Reason For Hope In CMG Pharmaceutical's (KOSDAQ:058820) Disappointing EarningsThe market for CMG Pharmaceutical Co., Ltd.'s ( KOSDAQ:058820 ) shares didn't move much after it posted weak earnings...
Reported Earnings • Nov 15Third quarter 2024 earnings released: ₩19.00 loss per share (vs ₩19.00 profit in 3Q 2023)Third quarter 2024 results: ₩19.00 loss per share (down from ₩19.00 profit in 3Q 2023). Revenue: ₩24.7b (up 5.0% from 3Q 2023). Net loss: ₩2.68b (down 199% from profit in 3Q 2023).
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.
New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 20% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: ₩43.00 (vs ₩27.00 in 2Q 2023)Second quarter 2024 results: EPS: ₩43.00 (up from ₩27.00 in 2Q 2023). Revenue: ₩24.9b (down 2.3% from 2Q 2023). Net income: ₩5.98b (up 62% from 2Q 2023). Profit margin: 24% (up from 14% in 2Q 2023).
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩2,000, the stock trades at a trailing P/E ratio of 46.3x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 59% over the past three years.
分析記事 • Mar 27CMG Pharmaceutical's (KOSDAQ:058820) Solid Earnings Are Supported By Other Strong FactorsCMG Pharmaceutical Co., Ltd. ( KOSDAQ:058820 ) just reported healthy earnings but the stock price didn't move much. We...
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Is New 90 Day High Low • Feb 24New 90-day low: ₩4,400The company is down 5.0% from its price of ₩4,630 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.
分析記事 • Dec 28Did You Participate In Any Of CMG Pharmaceutical's (KOSDAQ:058820) Fantastic 203% Return ?It's been a soft week for CMG Pharmaceutical Co., Ltd. ( KOSDAQ:058820 ) shares, which are down 13%. But that doesn't...
Is New 90 Day High Low • Dec 18New 90-day high: ₩6,350The company is up 38% from its price of ₩4,605 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Dec 02New 90-day high: ₩5,050The company is up 11% from its price of ₩4,540 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day high: ₩4,900The company is up 13% from its price of ₩4,355 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
